{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:32:48Z","timestamp":1784921568533,"version":"3.55.0"},"reference-count":141,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"AIRC fellowship for Italy","doi-asserted-by":"publisher","award":["26563-2021"],"award-info":[{"award-number":["26563-2021"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with a highly variable clinical course. Improvement in the knowledge of the molecular pathways behind this disease has led to the development of increasingly specific therapies, such as BCR signaling inhibitors and BCL-2 inhibitors. In this context, the emerging role of microRNAs (miRNAs) in CLL pathophysiology and their possible application in therapy is worth noting. MiRNAs are one of the most important regulatory molecules of gene expression. In CLL, they can act both as oncogenes and tumor suppressor genes, and the deregulation of specific miRNAs has been associated with prognosis, progression, and drug resistance. In this review, we describe the role of the miRNAs that primarily impact the disease, and how these miRNAs could be used as therapeutic tools. Certainly, the use of miRNAs in clinical practice is still limited in CLL. Many issues still need to be solved, particularly regarding their biological and safety profile, even if several studies have suggested their efficacy on the disease, alone or in combination with other drugs.<\/jats:p>","DOI":"10.3390\/ijms241512471","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T10:21:39Z","timestamp":1691230899000},"page":"12471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Role of microRNAs in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"24","author":[{"given":"Francesco","family":"Autore","sequence":"first","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ramassone","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), G. d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stirparo","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6648","authenticated-orcid":false,"given":"Sara","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), G. d\u2019Annunzio University, 66100 Chieti, Italy"},{"name":"Department of Medical, Oral and Biotechnological Sciences, G. d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9009","authenticated-orcid":false,"given":"Alberto","family":"Fresa","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Visone","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), G. d\u2019Annunzio University, 66100 Chieti, Italy"},{"name":"Department of Medical, Oral and Biotechnological Sciences, G. d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy"},{"name":"Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic Lymphocytic Leukemia","volume":"64","author":"Ghia","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute-Working Group 1996 Guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From Pathogenesis to Treatment of Chronic Lymphocytic Leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","article-title":"Chronic Lymphocytic Leukemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"22","author":"Eichhorst","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.4049\/jimmunol.1402304","article-title":"Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase \u03b4 but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells","volume":"194","author":"Till","year":"2015","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib Inhibits BCR and NF-\u039aB Signaling and Reduces Tumor Proliferation in Tissue-Resident Cells of Patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Byrd, J.C., Brown, J.R., O\u2019Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., and Jaeger, U. (2014). Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N. Engl. J. Med., 371.","DOI":"10.1056\/NEJMoa1400376"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as Initial Therapy for Elderly Patients with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b\/2 Trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","article-title":"Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician","volume":"32","author":"Byrd","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Zelenetz, A.D., Kipps, T.J., and Flinn, I. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 370.","DOI":"10.1056\/NEJMoa1315226"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an Inhibitor of Phosphatidylinositol 3-Kinase P110\u03b4, for Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s Tyrosine Kinase Inhibitors: First and Second Generation Agents for Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1215637","article-title":"Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation","volume":"9","author":"Hayder","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent Deletions and Down-Regulation of Micro-RNA Genes MiR15 and MiR16 at 13q14 in Chronic Lymphocytic Leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4614-8051-8_14","article-title":"MiR Deregulation in CLL","volume":"792","author":"Balatti","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-4598-9-123","article-title":"MicroRNAs Involvement in Fludarabine Refractory Chronic Lymphocytic Leukemia","volume":"9","author":"Ferracin","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA Profiling Reveals Distinct Signatures in B Cell Chronic Lymphocytic Leukemias","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/0008-5472.CAN-07-3105","article-title":"Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14","volume":"68","author":"Ouillette","year":"2008","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1073\/pnas.2118752119","article-title":"A Large Fraction of Trisomy 12, 17p2,and 11q2 CLL Cases Carry Unidenti Fi Ed Microdeletions of MiR-15a\/16-1","volume":"119","author":"Pepe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1182\/blood-2007-02-071225","article-title":"Abnormal MicroRNA-16 Locus with Synteny to Human 13q14 Linked to CLL in NZB Mice","volume":"109","author":"Raveche","year":"2007","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kasar, S., Underbayev, C., Hassan, M., Ilev, I., Degheidy, H., Bauer, S., Marti, G., Lutz, C., Raveche, E., and Batish, M. (2016). Alterations in the MiR-15a\/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL). PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149331"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/leu.2014.139","article-title":"Allele-Specific Loss and Transcription of the MiR-15a\/16-1 Cluster in Chronic Lymphocytic Leukemia","volume":"29","author":"Veronese","year":"2015","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.yexcr.2009.07.001","article-title":"DLEU2, Frequently Deleted in Malignancy, Functions as a Critical Host Gene of the Cell Cycle Inhibitory MicroRNAs MiR-15a and MiR-16-1","volume":"315","author":"Lerner","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/onc.2013.291","article-title":"Therapeutic Implications of Activation of the Host Gene (Dleu2) Promoter for MiR-15a\/16-1 in Chronic Lymphocytic Leukemia","volume":"33","author":"Kasar","year":"2014","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","article-title":"Histone Deacetylases Mediate the Silencing of MiR-15a, MiR-16, and MiR-29b in Chronic Lymphocytic Leukemia","volume":"119","author":"Sampath","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/leu.2013.246","article-title":"Defective DROSHA Processing Contributes to Downregulation of MiR-15\/-16 in Chronic Lymphocytic Leukemia","volume":"28","author":"Allegra","year":"2014","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"MiR-15 and MiR-16 Induce Apoptosis by Targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and MiR-16-1 Cluster Functions in Human Leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/MiR-15a\/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"MicroRNA Dysregulation to Identify Therapeutic Target Combinations for Chronic Lymphocytic Leukemia","volume":"114","author":"Rassenti","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.13043","article-title":"Loss of MIR15A and MIR16-1 at 13q14 Is Associated with Increased TP53 MRNA De-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia","volume":"167","author":"Lin","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2010.1919","article-title":"Association of a MicroRNA\/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia","volume":"305","author":"Fabbri","year":"2011","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/leu.2016.394","article-title":"Effects of MiRNA-15 and MiRNA-16 Expression Replacement in Chronic Lymphocytic Leukemia: Implication for Therapy","volume":"31","author":"Cutrona","year":"2017","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gene.2011.58","article-title":"Systemic in Vivo Lentiviral Delivery of MiR-15a\/16 Reduces Malignancy in the NZB de Novo Mouse Model of Chronic Lymphocytic Leukemia","volume":"13","author":"Kasar","year":"2012","journal-title":"Genes Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5507\/bp.2014.029","article-title":"The Role of miR-29 Family Members in Malignant Hematopoiesis","volume":"158","author":"Kollinerova","year":"2014","journal-title":"Biomed. Pap."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jcb.29896","article-title":"The Role of miR-29 Family in Disease","volume":"122","author":"Horita","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread MicroRNA Repression by Myc Contributes to Tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","article-title":"Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181","volume":"66","author":"Pekarsky","year":"2006","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.leu.2404017","article-title":"TCL1 Shows a Regulated Expression Pattern in Chronic Lymphocytic Leukemia That Correlates with Molecular Subtypes and Proliferative State","volume":"20","author":"Herling","year":"2006","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12210","DOI":"10.1073\/pnas.1007186107","article-title":"Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression","volume":"107","author":"Santanam","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.18632\/oncotarget.129","article-title":"Is miR-29 an Oncogene or Tumor Suppressor in CLL?","volume":"1","author":"Pekarsky","year":"2010","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/sj.onc.1210436","article-title":"MiR-29 Regulates Mcl-1 Protein Expression and Apoptosis","volume":"26","author":"Mott","year":"2007","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood.2020005627","article-title":"MiR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors","volume":"137","author":"Sharma","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L Signals from Autologous T Cells Can Induce Antigen-Independent Proliferation of CLL Cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood.2018882290","article-title":"ROR1-Targeted Delivery of MiR-29b Induces Cell Cycle Arrest and Therapeutic Benefit in Vivo in a CLL Mouse Model","volume":"134","author":"Chiang","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human MicroRNA Genes Are Frequently Located at Fragile Sites and Genomic Regions Involved in Cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1182\/blood-2009-07-192740","article-title":"Chronic Lymphocytic Leukemia: Interplay between Noncoding RNAs and Protein-Coding Genes","volume":"114","author":"Calin","year":"2009","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A MicroRNA Component of the P53 Tumour Suppressor Network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V112.11.2074.2074","article-title":"Invariant Deletion of One miR-34b\/c Locus in CLL with Del11q","volume":"112","author":"Malek","year":"2008","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2009-07-234823","article-title":"MicroRNA-34a Expression Correlates with MDM2 SNP309 Polymorphism and Treatment-Free Survival in Chronic Lymphocytic Leukemia","volume":"115","author":"Asslaber","year":"2010","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2008-08-172254","article-title":"MiR-34a as Part of the Resistance Network in Chronic Lymphocytic Leukemia","volume":"113","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed Analysis of P53 Pathway Defects in Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL): Dissecting the Contribution of 17p Deletion, TP53 Mutation, P53-P21 Dysfunction, and MiR34a in a Prospective Clinical Trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41375-018-0230-x","article-title":"MicroRNA miR-34a Downregulates FOXP1 during DNA Damage Response to Limit BCR Signalling in Chronic Lymphocytic Leukaemia B Cells","volume":"33","author":"Cerna","year":"2019","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2018-04-845115","article-title":"MiR-125a and miR-34a Expression Predicts Richter Syndrome in Chronic Lymphocytic Leukemia Patients","volume":"132","author":"Balatti","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the P53 Network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nrc2232","article-title":"MicroRNAs Join the P53 Network\u2014Another Piece in the Tumour-Suppression Puzzle","volume":"7","author":"He","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 Mutation and Survival in Chronic Lymphocytic Leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Campo, E., Cymbalista, F., Ghia, P., J\u00e4ger, U., Pospisilova, S., Rosenquist, R., Schuh, A., and Stilgenbauer, S. (2018). TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica, 103.","DOI":"10.3324\/haematol.2018.187583"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.264","article-title":"17p13\/TP53 Deletion in B-CLL Patients Is Associated with MicroRNA-34a Downregulation","volume":"23","author":"Dijkstra","year":"2009","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2008.377","article-title":"MiR-34a, MiR-29c and MiR-17-5p Are Downregulated in CLL Patients with TP53 Abnormalities","volume":"23","author":"Mraz","year":"2009","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-P53 Pathway Revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the P53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.2007.11.5212","article-title":"MDM2 SNP309 Is Associated with Poor Outcome in B-Cell Chronic Lymphocytic Leukemia","volume":"26","author":"Gryshchenko","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1479-5876-12-52","article-title":"Epigenetic Inactivation of miR-34b\/c in Addition to miR-34a and DAPK1 in Chronic Lymphocytic Leukemia","volume":"12","author":"Wang","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4161\/epi.28603","article-title":"MicroRNA-34b\/c on Chromosome 11q23 Is Aberrantly Methylated in Chronic Lymphocytic Leukemia","volume":"9","author":"Deneberg","year":"2014","journal-title":"Epigenetics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1038\/mtna.2014.47","article-title":"MiR-34: A New Weapon against Cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 Study of MRX34, a Liposomal miR-34a Mimic, in Patients with Advanced Solid Tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I Study of MRX34, a Liposomal miR-34a Mimic, Administered Twice Weekly in Patients with Advanced Solid Tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging Concepts of MiRNA Therapeutics: From Cells to Clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-03-3773","article-title":"Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-Q32 Amplification in Malignant Lymphoma","volume":"64","author":"Ota","year":"2004","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chocholska, S., Zarobkiewicz, M., Szyma\u0144ska, A., Lehman, N., Wo\u015b, J., and Bojarska-Junak, A. (2023). Prognostic Value of the MiR-17-92 Cluster in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021705"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1038\/s41598-022-11090-2","article-title":"High Expression of MiR-17-5p and MiR-20a-5p Predicts Favorable Disease-Specific Survival in Stage I-III Colon Cancer","volume":"12","author":"Selven","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jfma.2018.04.013","article-title":"MiR-17-92 Cluster and Immunity","volume":"118","author":"Kuo","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood-2011-09-378687","article-title":"The miR-17-92 Cluster Expands Multipotent Hematopoietic Progenitors Whereas Imbalanced Expression of Its Individual Oncogenic MiRNAs Promotes Leukemia in Mice","volume":"119","author":"Li","year":"2012","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/leu.2012.44","article-title":"The MiR-17-92 Family Regulates the Response to Toll-like Receptor 9 Triggering of CLL Cells with Unmutated IGHV Genes","volume":"26","author":"Bomben","year":"2012","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/emboj.2008.85","article-title":"Zbtb4 Represses Transcription of P21CIP1 and Controls the Cellular Response to P53 Activation","volume":"27","author":"Weber","year":"2008","journal-title":"EMBO J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of MicroRNA Function by AntimiR Oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of MicroRNAs in Vivo with \u2018Antagomirs\u2019","volume":"438","author":"Rajewsky","year":"2005","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-014-0079-z","article-title":"Potential Therapeutic Role of AntagomiR17 for the Treatment of Chronic Lymphocytic Leukemia","volume":"7","author":"Dereani","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1139253","article-title":"Requirement of Bic\/MicroRNA-155 for Normal Immune Function","volume":"316","author":"Rodriguez","year":"2007","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.0610731104","article-title":"MicroRNA-155 Is Induced during the Macrophage Inflammatory Response","volume":"104","author":"Taganov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","article-title":"MicroRNA-155 Induction via TNF-\u03b1 and IFN-\u03b3 Suppresses Expression of Programmed Death Ligand-1 (PD-L1) in Human Primary Cells","volume":"292","author":"Yee","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbrc.2007.10.077","article-title":"Expression Patterns of MicroRNAs 155 and 451 during Normal Human Erythropoiesis","volume":"364","author":"Masaki","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014MicroRNAs with a Role in Cancer","volume":"6","author":"Slack","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ijc.22800","article-title":"MicroRNA Expression Distinguishes between Germinal Center B Cell-like and Activated B Cell-like Subtypes of Diffuse Large B Cell Lymphoma","volume":"121","author":"Lawrie","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/gcc.10186","article-title":"High Expression of B-Cell Receptor Inducible Gene BIC in All Subtypes of Hodgkin Lymphoma","volume":"37","author":"Kroesen","year":"2003","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/path.1825","article-title":"BIC and miR-155 Are Highly Expressed in Hodgkin, Primary Mediastinal and Diffuse Large B Cell Lymphomas","volume":"207","author":"Kluiver","year":"2005","journal-title":"J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-5-26","article-title":"MiR-424 and miR-155 Deregulated Expression in Cytogenetically Normal Acute Myeloid Leukaemia: Correlation with NPM1 and FLT3 Mutation Status","volume":"5","author":"Faraoni","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2006-12-062398","article-title":"Quantitative Technologies Establish a Novel MicroRNA Profile of Chronic Lymphocytic Leukemia","volume":"109","author":"Fulci","year":"2007","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A MicroRNA Expression Signature of Human Solid Tumors Defines Cancer Gene Targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/ijc.22394","article-title":"Expression Profiling Identifies MicroRNA Signature in Pancreatic Cancer","volume":"120","author":"Lee","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbadis.2009.02.013","article-title":"MiR-155 Gene: A Typical Multifunctional MicroRNA","volume":"1792","author":"Faraoni","year":"2009","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1210\/jc.2007-2696","article-title":"MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility","volume":"93","author":"Nikiforova","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/dna.2006.0554","article-title":"MiRNA Profiling for Diagnosis and Prognosis of Human Cancer","volume":"26","author":"Jay","year":"2007","journal-title":"DNA Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1128\/MCB.17.3.1490","article-title":"Bic, a Novel Gene Activated by Proviral Insertions in Avian Leukosis Virus-Induced Lymphomas, Is Likely to Function through Its Noncoding RNA","volume":"17","author":"Tam","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-1119(01)00612-6","article-title":"Identification and Characterization of Human BIC, a Gene on Chromosome 21 That Encodes a Noncoding RNA","volume":"274","author":"Tam","year":"2001","journal-title":"Gene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0960-9822(02)00809-6","article-title":"Identification of Tissue-Specific MicroRNAs from Mouse","volume":"12","author":"Rauhut","year":"2002","journal-title":"Curr. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1182\/blood-2010-04-280156","article-title":"MiR-155 and Its Star-Form Partner MiR-155* Cooperatively Regulate Type I Interferon Production by Human Plasmacytoid Dendritic Cells","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.18632\/oncotarget.2390","article-title":"Methylation of MiR-155-3p in Mantle Cell Lymphoma and Other Non-Hodgkin\u2019s Lymphomas","volume":"5","author":"Yim","year":"2014","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.2147\/OTT.S206180","article-title":"MicroRNA-155-3p Promotes Breast Cancer Progression through down-Regulating CADM1","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco. Targets. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"220070","DOI":"10.1098\/rsob.220070","article-title":"MiR-155-3p: Processing by-Product or Rising Star in Immunity and Cancer?","volume":"12","author":"Dawson","year":"2022","journal-title":"Open Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14348\/molcells.2017.2303","article-title":"Transforming Growth Factor \u03921\/Smad4 Signaling Affects Osteoclast Differentiation via Regulation of miR-155 Expression","volume":"40","author":"Zhao","year":"2017","journal-title":"Mol. Cells"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1128\/JVI.00570-11","article-title":"Oncogenic IRFs Provide a Survival Advantage for Epstein-Barr Virus- or Human T-Cell Leukemia Virus Type 1-Transformed Cells through Induction of BIC Expression","volume":"85","author":"Wang","year":"2011","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1074\/jbc.M708218200","article-title":"B-Cell Receptor Activation Induces BIC\/MiR-155 Expression through a Conserved AP-1 Element","volume":"283","author":"Yin","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1074\/jbc.M113.522730","article-title":"The Role of Ets2 Transcription Factor in the Induction of Microrna-155 (MiR-155) by Lipopolysaccharide and Its Targeting by Interleukin-10","volume":"289","author":"Quinn","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/MCB.01276-10","article-title":"MicroRNA-155 Promotes Resolution of Hypoxia-Inducible Factor 1\u03b1 Activity during Prolonged Hypoxia","volume":"31","author":"Bruning","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1093\/nar\/gkn666","article-title":"Epstein-Barr Virus Latent Membrane Protein 1 Trans-Activates miR-155 Transcription through the NF-\u039aB Pathway","volume":"36","author":"Gatto","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in Human B Cell Lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2013-01-478222","article-title":"Prognostic Value of miR-155 in Individuals with Monoclonal B-Cell Lymphocytosis and Patients with B Chronic Lymphocytic Leukemia","volume":"122","author":"Ferrajoli","year":"2013","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.0602266103","article-title":"Pre-B Cell Proliferation and Lymphoblastic Leukemia\/High-Grade Lymphoma in E\u03bc-MiR155 Transgenic Mice","volume":"103","author":"Costinean","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1182\/blood-2010-05-285064","article-title":"MYB Transcriptionally Regulates the miR-155 Host Gene in Chronic Lymphocytic Leukemia","volume":"117","author":"Vargova","year":"2011","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","article-title":"Micro RNA-155 Influences B-Cell Receptor Signaling and Associates with Aggressive Disease in Chronic Lymphocytic Leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"13036","DOI":"10.18632\/oncotarget.24437","article-title":"Hsa-MiR-155-5p Drives Aneuploidy at Early Stages of Cellular Transformation","volume":"9","author":"Pagotto","year":"2018","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Pagotto, S., Veronese, A., Soranno, A., Balatti, V., Ramassone, A., Guanciali-Franchi, P.E., Palka, G., Innocenti, I., Autore, F., and Rassenti, L.Z. (2019). Hnrnpl Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11040575"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V128.22.1829.1829","article-title":"Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic MicroRNA Antagonist (LNA AntimiR) of MicroRNA-155, in Patients with CTCL","volume":"128","author":"Querfeld","year":"2016","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an Oligonucleotide Inhibitor of MiR-155, Slows DLBCL Tumor Cell Growth in Vitro and in Vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tcm.2013.09.002","article-title":"Role of MiR-181 Family in Regulating Vascular Inflammation and Immunity","volume":"24","author":"Sun","year":"2014","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2011-01-333484","article-title":"MiR-181b Is a Biomarker of Disease Progression in Chronic Lymphocytic Leukemia","volume":"118","author":"Visone","year":"2011","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.18632\/oncotarget.448","article-title":"MiR-181b: New Perspective to Evaluate Disease Progression in Chronic Lymphocytic Leukemia","volume":"3","author":"Visone","year":"2012","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.leu.2405022","article-title":"Small RNAs Analysis in CLL Reveals a Deregulation of MiRNA Expression and Novel MiRNA Candidates of Putative Relevance in CLL Pathogenesis","volume":"22","author":"Marton","year":"2008","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Li, S., Moffett, H.F., Lu, J., Werner, L., Zhang, H., Ritz, J., Neuberg, D., Wucherpfennig, K.W., Brown, J.R., and Novina, C.D. (2011). Microrna Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016956"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted TCL1 Expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/carcin\/bgs179","article-title":"MiR-181a\/b Significantly Enhances Drug Sensitivity in Chronic Lymphocytic Leukemia Cells via Targeting Multiple Anti-Apoptosis Genes","volume":"33","author":"Zhu","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.beha.2007.02.003","article-title":"The Role of MicroRNA and Other Non-Coding RNA in the Pathogenesis of Chronic Lymphocytic Leukemia","volume":"20","author":"Calin","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3109\/10428194.2013.796055","article-title":"MicroRNAs and B Cell Receptor Signaling in Chronic Lymphocytic Leukemia","volume":"54","author":"Mraz","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/10428190902763517","article-title":"MicroRNAs in Chronic Lymphocytic Leukemia Pathogenesis and Disease Subtypes","volume":"50","author":"Mraz","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","article-title":"Hematopoietic-Specific MicroRNA Expression in Human Cells","volume":"30","author":"Ramkissoon","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/ijc.25260","article-title":"MiR-181b Modulates Multidrug Resistance by Targeting BCL2 in Human Cancer Cell Lines","volume":"127","author":"Zhu","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1073\/pnas.0810965105","article-title":"Tcl1 Functions as a Transcriptional Regulator and Is Directly Involved in the Pathogenesis of CLL","volume":"105","author":"Pekarsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent Up-Regulation of BCL-XL and BCL2A1 Induces Approximately 1000-Fold Resistance to ABT-737 in Chronic Lymphocytic Leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"19807","DOI":"10.18632\/oncotarget.4415","article-title":"MiR-181b as a Therapeutic Agent for Chronic Lymphocytic Leukemia in the E\u03bc-TCL1 Mouse Model","volume":"6","author":"Bresin","year":"2015","journal-title":"Oncotarget"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Di Marco, M., Veschi, S., Lanuti, P., Ramassone, A., Pacillo, S., Pagotto, S., Pepe, F., George-William, J.N., Curcio, C., and Marchisio, M. (2021). Enhanced Expression of miR-181b in b Cells of Cll Improves the Anti-Tumor Cytotoxic t Cell Response. Cancers, 13.","DOI":"10.3390\/cancers13020257"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:26:29Z","timestamp":1760127989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":141,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241512471"],"URL":"https:\/\/doi.org\/10.3390\/ijms241512471","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]}}}